Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

40.4% of patients who received CagriSema reached a weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with placebo.

Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

The stock recently declined after the company released results from a Phase 3 trial of subcutaneous CagriSema, a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, which showed ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

The amycretin data look stronger than the 19% weight loss at 36 weeks generated for Lilly's own next-generation drug retatrutide in phase 2 (phase 3 data expected in 2026), and 20.4% cagrisema ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.